Skip to main content

Table 2 Multivariate analysis results showing the prognostic value of different clinicopathological parameters

From: Prostate-specific antigen nadir within 1 year of radiotherapy combined with hormone therapy predicts cancer-specific mortality and biochemical recurrence-free survival in prostate cancer patients

 

OS

PCSM

BRFS

 

HR

p

HR

p

HR

p

Age

1.9(1.2–3.1)

0.004

    

HT period

  

2.8(1.1–6.9)

0.02

  

RT field

2.1(1.1–3.9)

0.015

3.8(1.3–10)

0.01

0.5(1.6–1.8)

0.3

RT Technic

  

0.5(0.1–1.9)

0.35

0.6(0.2–1.9)

0.45

PSA nadir

1.9(1.1–3.1)

0.008

3.9(1.7–9.3)

0.001

2(0.9–4.1)

0.04

Time to nadir PSA

0.9(0.6–1.6)

0.952

2.4(1-5.6)

0.042

2.1(1.1-4)

0.021

  1. OS: Overall survival, PCSM; prostate cancer specific mortality, BRFS: biochemical recurrence-free survival, HT: hormonotherapy, RT: radiotherapy, HR: hazard ratio